Bristol Myers Squibb Presents New Interim Long-Term Efficacy Data from the EMERGENT-4 Trial Evaluating KarXT in Schizophrenia at the 2024 Annual Congress of the Schizophrenia International Research Society – Zai Lab Limited
Saturday, April 6, 2024 BiopharmaWatch Research 1 min read
Key Takeaway: Bristol Myers Squibb Presents New Interim Long-Term Efficacy Data from the EMERGENT-4 Trial Evaluating KarXT in Schizophrenia at the 2024 Annual Congress of the Schizophrenia International Research Society – Zai Lab Limited
Price reaction · baseline $15.52 (2024-04-05 close) · hit after-hours · 1 other ZLAB headline(s) in the window, move may be shared
day 0 close
-0.2%
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+60%
120-day peak, hindsight
Typical move
2.2%
average across 15 past catalysts
Cash runway
~28 mo
Low dilution risk
Lead asset
ZL-1310
Phase 3 · Small-cell Lung Cancer
Full Press Release Details
Bristol Myers Squibb Presents New Interim Long-Term Efficacy Data from the EMERGENT-4 Trial Evaluating KarXT in Schizophrenia at the 2024 Annual Congress of the Schizophrenia International Research Society – Zai Lab Limited.